Clene

Clene

Clene was founded in 2012 and later relocated its headquarters to Salt Lake City, where it operates a drug-manufacturing subsidiary. The company's core asset is a suspension of clean-surfaced platinum nanocrystals — branded CNM-Au8 — designed to cross the blood-brain barrier and improve neuronal metabolic function. This mechanism, which targets bioenergetic failure rather than a specific protein aggregate, puts Clene adjacent to but distinct from the amyloid-targeting strategies that dominate the Alzheimer's field. The company has concentrated its clinical resources on two primary indications: amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). In ALS, the HEALEY ALS Platform Trial evaluated CNM-Au8 as a potential disease-modifying therapy, with results showing a signal for survival benefit in a prespecified subgroup but missing the primary endpoint in the overall population. The company continues to engage with the FDA to define a regulatory path. In MS, Clene has reported data from the VISIONARY-MS trial, focusing on visual evoked potential as a functional biomarker of remyelination. Confirmed past financing partners include SymBiosis Capital, which led a pre-IPO round prior to the 2021 business combination with Tottenham Acquisition I Limited. As of May 2026, the firm remains a publicly traded micro-cap (NASDAQ: CLNN) operating without a revenue-generating drug product. It funds clinical operations through secondary equity offerings and grant mechanisms, including past awards from the National Multiple Sclerosis Society. The organization employs a small internal team supplemented by contract research organizations for trial execution. A notable adjacent entity is Clene Nanomedicine, the wholly-owned manufacturing arm that produces the nanocrystal suspension. In December 2024, the firm announced its President and CEO Rob Etherington would present at a virtual investor conference hosted by H.C. Wainwright. Clene's structural differentiator lies in its manufacturing-integrated model: it controls the production of its own drug substance through a scalable nanotechnology process, making it less reliant on complex biologic supply chains than many early-stage biotechs. This vertical integration gives it a potential cost-of-goods advantage if a drug reaches commercialization, though it also concentrates operational risk in a single facility.